

provide--

On page 13, line 23, change "(A) and MC38 cells (B)" to --(Figure 18A) and MC38 cells (Figure 18B)--.

On page 13, line 30, change "Figure 19 shows" to --Figures 19A-B show--.

On page 13, line 35, change "8A" to --19A--.

On page 14, line 2, change "8B" to --19B--.

In the Claims:

Please amend claims 1-2 and 6 as follows:

Sub 431
1. (Amended) A chimeric molecule suitable for stimulating a tumor specific immune response comprising:
a binding domain having an N terminus and being capable of specifically binding to a tumor cell associated antigen, and
a chemokine or active fragment thereof, which is [associated with] coupled to the N terminus of the binding domain such that the binding domain remains capable of binding to the tumor cell associated antigen and the chemokine retains activity.

2. (Amended) The chimeric molecule according to claim 1, wherein the binding domain is an antibody or fragment thereof which specifically binds to the tumor cell associated antigen.

Sub 433
A6
6. (Amended) The chimeric molecule according to claim 1, wherein the chemokine is selected from the group consisting of DC-CK1, SDF-1, fractalkine, lymphotactin, IP-10, Mig, MCAF, MIP-1 α , MIP-1 β , IL-8, NAP-2, PF-4, [and] RANTES, [or an] and active fragments thereof.

REMARKS

In view of the above amendments and the following remarks, reconsideration of the outstanding office action is respectfully requested.